Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUMP IV trial of adjuvant hepatic arterial infusion pump chemotherapy after resection of intrahepatic cholangiocarcinoma
NL-OMON57237Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of floxuridine in intrahepatic cholangiocarcinoma (ICC) and cholangiocarcinoma (CCA) (2 arms), sponsored by Erasmus MC. Primary endpoint: Rate of intrahepatic recurrence at 2 years. Started Oct 2024; status: recruiting.
02
Drugs
floxuridine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NL-OMON57237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57237.